BPC-157: How It Works, What It's Studied For & Safety
BPC-157 is a 15-amino-acid sequence derived from a protein in human gastric juice, studied extensively in preclinical models for its effect on tendon, ligament, and gut mucosa repair. Clinicians consider it for tendon, ligament, and connective-tissue repair models. Not FDA-approved; dispensed by Wells Pharmacy Network only after a clinician evaluation.
Also known as: Body Protective Compound 157, Pentadecapeptide BPC-157
How does BPC-157 work?
BPC-157 is studied for upregulation of growth-hormone-receptor expression in tendon fibroblasts and for promotion of vascular endothelial growth factor (VEGF) signaling. The literature describes accelerated tendon-to-bone healing, modulation of nitric-oxide pathways, and protective effects on gastric and intestinal mucosa in rodent models.
What is BPC-157 studied for?
- Tendon, ligament, and connective-tissue repair models
- Gastric and intestinal mucosa healing research
- Joint pain associated with tendinopathy in clinician-directed protocols
- Recovery support after orthopedic procedures
How is BPC-157 taken?
Compounded as a subcutaneous injection (most common in clinician protocols) or, less commonly, as an oral preparation when GI-targeted use is the goal. Cycles are typically four to six weeks under clinician oversight.
Is BPC-157 FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. The FDA placed BPC-157 on its Category 2 bulks list in 2023, restricting its use in 503A compounding. Eligibility for any current preparation is determined by your clinician. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
This compound does not currently appear in an active Regen Therapy protocol. Browse the full catalog for adjacent options.
What does the research say about BPC-157?
More than 100 peer-reviewed preclinical papers. No registered phase-2 or phase-3 human trials have established efficacy or long-term safety. Clinical use is research-informed and individualized.
Citations & further reading
Considering BPC-157 as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →